Benzinga | Feb 25, 2021 10:22AM EST

Roth Capital Maintains Buy on OptimizeRx, Raises Price Target to $85

Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $70 to $85.